Under the agreement signed, Technology Development Board and Bharat Biotech have pledged support of Rs 200 crore each to create a continuous corpus of Rs 400 crore for development and commercialisation of two novel vaccines –‘Intranasal COVID-19 Vaccine’ and ‘RTS, S Malaria Vaccine’.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/vRinEgy
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» TDB, Sapigen Biologix ink agreement to commercialise intranasal COVID-19, RTS, S Malaria vaccine
https://ift.tt/16TYuRC
No comments:
Post a Comment